Results 231 to 240 of about 902,578 (275)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

100 m climate and heat stress data up to 2100 for 142 cities around the globe. [PDF]

open access: yesData Brief
Souverijns N   +6 more
europepmc   +1 more source

Digital Inventory of Swiss Construction Systems. [PDF]

open access: yesSci Data
Arceo A   +3 more
europepmc   +1 more source

Policymaker-led scenarios and public dialogue facilitate energy demand analysis for net-zero futures. [PDF]

open access: yesNat Energy
Sharmina M   +10 more
europepmc   +1 more source

COLLECTiEF dataset: A high-resolution indoor environmental dataset from European buildings across diverse climates supporting thermal, air-quality, and visual-comfort assessments. [PDF]

open access: yesData Brief
Campodonico-Avendano IA   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy